Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/TAJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatocellular carcinoma (HCC) discusses the data for use of first-line immunotherapy-based combination regimens in patients with unresectable HCC. Upon completion of this activity, participants should be better able to: Review the clinical significance of the long-term evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; Identify patients with unresectable HCC who are appropriate for first-line immunotherapy-based combination regimens; and Outline an individualized, long-term treatment plan that balances the risks and benefits of first-line immunotherapy-based combination regimens for patients with unresectable HCC.

Please visit answersincme.com/MWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in coagulation disorders discusses the clinical impact of gene therapy in hemophilia A. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of gene therapy in the treatment of hemophilia A; Identify patients with hemophilia A who may be candidates for gene therapy; and Outline patient-centered monitoring strategies to optimize outcomes in patients with hemophilia A undergoing gene therapy.

Please visit answersincme.com/RPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available third-line therapies for patients with chronic myeloid leukemia. Upon completion of this activity, participants should be better able to: Describe treatment challenges with available therapeutic options as chronic myeloid leukemia (CML) progresses; Review the available clinical data for third-line agents in CML; and Differentiate between third-line CML treatments based on patient, drug, and disease factors.

Please visit answersincme.com/UJD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in transgender medicine discusses improving approaches to guideline-concordant cervical cancer screening by healthcare professionals in patients who are transgender men or nonbinary. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of low uptake of cervical cancer screening among transgender men (TM) and people who identify as nonbinary (NB); Review key concerns experienced by TM and NB people that result in lower rates of cervical cancer screening; and Identify tailored strategies to enhance acceptance of cervical cancer screening in TM and people who identify as NB.

Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.

Please visit answersincme.com/EKH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses frontline immunotherapy-based combination strategies to improve outcomes in patients with advanced biliary tract cancer. Upon completion of this activity, participants should be better able to: Review the rationale for including immunotherapy as a component of a therapeutic approach for patients with advanced biliary tract cancer (BTC); Describe the clinical profiles of immunotherapy plus chemotherapy combinatorial approaches for the treatment of advanced BTC; and Outline practical strategies to enhance evidence-based care of patients with advanced BTC on a combined immunotherapy plus chemotherapy approach.

Please visit answersincme.com/WGA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of triplet therapy for patients with metastatic hormone-sensitive prostate cancer. Upon completion of this activity, participants should be better able to: Discuss recommended, evidence-based triplet therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC); Recognize patient and disease factors that can guide the selection of triplet treatment strategies for mHSPC; and Explain how to minimize adverse events for patients being treated with triplet therapy for mHSPC.

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.